Blockchain Registration Transaction Record

VolitionRx's Nu.Q Assay Shows Prognostic Value in Lung Cancer Study

VolitionRx's Nu.Q Cancer Assay shows prognostic value in lung cancer, stratifying patients into risk groups. Study with Hospices Civils de Lyon supports personalized treatment. Reimbursement submission in France underway.

This study matters because it could revolutionize how lung cancer patients are managed. By using a simple blood test to accurately stratify risk, doctors can personalize treatment plans, potentially improving survival rates and reducing unnecessary side effects. For patients, this means more targeted, effective care from the moment of diagnosis. For healthcare systems, it offers a cost-effective tool to optimize resources and improve outcomes. VolitionRx's progress toward reimbursement in France also signals a step toward broader clinical adoption, making this technology accessible to more patients worldwide.